journal
MENU ▼
Read by QxMD icon Read
search

Breast Care

journal
https://www.readbyqxmd.com/read/29235588/erratum
#1
(no author information available yet)
[This corrects the article DOI: 10.1159/000463377.].
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234257/dual-her2-blockade
#2
Christoph Thomssen, Nagi S El Saghir, Prudence A Francis, Jacek Jassem, Hope S Rugo, Michael Untch
No abstract text is available yet for this article.
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234256/congenital-malformations-of-the-reproductive-tract-in-a-patient-with-poland-syndrome-is-there-a-connection
#3
Tian Meng, Ming Bai, Ru Zhao
Background: Poland syndrome and Müllerian duct agenesis (Mayer-Rokitansky-Küster-Hauser(MRKH)-like syndrome) are two rare congenital anomalies with unclear etiology. Case Report: An 18-year-old female presented with hypoplasia of the left pectoralis muscles and subcutaneous tissue, hypoplasia of the left breast and nipple, and dextrocardia, typical in those with a severe form of Poland syndrome. She also showed aplasia of the vagina and uterus, bilateral ovarian agenesis, and hyperandrogenism, presenting as MRKH-like syndrome...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234255/influence-of-orally-administered-probiotic-lactobacillus-strains-on-vaginal-microbiota-in-women-with-breast-cancer-during-chemotherapy-a-randomized-placebo-controlled-double-blinded-pilot-study
#4
Julian Marschalek, Alex Farr, Marie-Louise Marschalek, Konrad J Domig, Wolfgang Kneifel, Christian F Singer, Herbert Kiss, Ljubomir Petricevic
Background: Due to chemotherapy and estrogen deprivation therapy, genitourinary syndrome of menopause is a common condition in breast cancer patients. We aimed to determine the effect of an orally administered Lactobacillus preparation on the vaginal microbiota in breast cancer patients. Methods: Postmenopausal breast cancer patients receiving chemotherapy, with vaginal atrophy and an intermediate vaginal microbiota (Nugent score 4-6), were either randomized to the intervention group receiving probiotic capsules of 4 Lactobacillus species or to the control group receiving placebo twice daily for 2 weeks...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234254/prognostic-significance-of-focal-adhesion-kinase-in-node-negative-breast-cancer
#5
Katrin Almstedt, Isabel Sicking, Marco J Battista, Shangou Huangfu, Anne-Sophie Heimes, Veronika Weyer-Elberich, Annette Hasenburg, Marcus Schmidt
Background: Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays an important role as a mediator of cell migration, invasion, proliferation and survival. Conflicting results for the prognostic role of FAK in breast cancer (BC) prompted us to determine its impact. Methods: Patients with node-negative BC entered this retrospective study. FAK expression was determined by immunohistochemistry (n = 335). The prognostic impact of FAK was examined with Cox regression analyses and Kaplan-Meier estimation in the whole cohort as well as in different molecular subtypes...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234253/evaluation-of-sentinel-lymph-node-biopsy-and-axillary-lymph-node-dissection-for-breast-cancer-treatment-concepts-a-retrospective-study-of-1-214-breast-cancer-patients
#6
Roland G Stein, Roland Fricker, Thomas Rink, Hartmut Fitz, Sebastian Blasius, Joachim Diessner, Sebastian F M Häusler, Tanja N Stüber, Victoria Andreas, Achim Wöckel, Thomas Müller
Background: Most breast cancer patients require lumpectomy with axillary sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). The ACOSOG Z0011-trial failed to detect significant effects of ALND on disease-free and overall survival among patients with limited sentinel lymph node (SLN) metastases. Intense dose-dense chemotherapy and supraclavicular fossa radiation (SFR) are indicated for patients with extensive axillary metastases. In this multicentered study, we investigated the relevance of ALND after positive SLNB to determine adequate adjuvant therapy...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234252/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy-a-subgroup-analysis-of-hormone-receptor-positive-her2-negative-breast-cancer
#7
Hans-Christian Kolberg, György Lövey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter Fasching, Michael Untch, Oliver Hoffmann, Max Bulsara, Jayant Vaidya, Cornelia Liedtke
Introduction: In a previous study our group showed a beneficial effect of targeted intraoperative radiotherapy (TARGIT-IORT) as an intraoperative boost on overall survival after neoadjuvant chemotherapy (NACT) compared to an external boost (EBRT). In this study we present the results of a detailed subgroup analysis of the hormone receptor (HR)-positive HER2-negative patients. Methods: In this cohort study involving 46 patients with HR-positive HER2-negative breast cancer after NACT, we compared the outcomes of 21 patients who received an IORT boost to those of 25 patients treated with an EBRT boost...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234251/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy
#8
EDITORIAL
Jayant S Vaidya, Jeffrey S Tobias
No abstract text is available yet for this article.
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234250/are-we-ready-to-use-esr1-mutations-in-clinical-practice
#9
REVIEW
Rinath Jeselsohn
The recurrent ligand-binding domain ESR1 mutations are an important mechanism of endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. These mutations evolve under the selective pressure of endocrine treatments and are rarely found in treatment-naïve ER+ breast cancers. Preclinical studies showed that these mutations lead to ligand-independent activity facilitating resistance to aromatase inhibitors and relative resistance to tamoxifen and fulvestrant. Retrospective analyses of ESR1 mutations in baseline plasma circulating tumor DNA from clinical trials suggest that these mutations are prognostic of poor overall survival and predictive of resistance to aromatase inhibitors in metastatic disease...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234249/mechanisms-of-resistance-to-cdk4-6-inhibitors-in-breast-cancer-and-potential-biomarkers-of-response
#10
REVIEW
Cristina Guarducci, Martina Bonechi, Giulia Boccalini, Matteo Benelli, Emanuela Risi, Angelo Di Leo, Luca Malorni, Ilenia Migliaccio
Randomized clinical trials demonstrated that CDK4/6 inhibitors are highly effective in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer in combination with endocrine therapy. The use of CDK4/6 inhibitors in clinics is becoming common for patients with HR+/HER2- metastatic breast cancer and will certainly increase in the near future. However, patients might show de novo or acquired resistance to these drugs. Molecular alterations have been suggested as determinants for de novo resistance to CDK4/6 inhibitors, but have never been validated in a clinical setting...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234248/incorporating-cdk4-6-inhibitors-in-the-treatment-of-advanced-luminal-breast-cancer
#11
REVIEW
Isabel Echavarria, Yolanda Jerez, Miguel Martin, Sara López-Tarruella
After optimizing endocrine monotherapy modalities in the setting of advanced luminal breast cancer (BC), dual endocrine/targeted therapy combinations have been tested with positive results, and are transforming this BC subtype treatment landscape. Cell cycle deregulation is a hallmark of cancer that has become a key druggable target in hormone receptor (HR)-positive BC due to its role in endocrine resistance mechanisms. Cyclin dependent kinase (CDK)4/6 inhibitors have experienced a fast development in combination with endocrine therapy and have already been commercialized in some countries...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234247/pi3k-mtor-inhibitors-in-the-treatment-of-luminal-breast-cancer-why-when-and-to-whom
#12
REVIEW
Francesco Schettini, Giuseppe Buono, Meghana V Trivedi, Sabino De Placido, Grazia Arpino, Mario Giuliano
Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in luminal breast cancer (BC). Despite the efficacy of endocrine agents, many patients with luminal BC do not respond to endocrine therapy and many others develop endocrine resistance over time, due to the activation of escape pathways such as the PI3K/AKT/mTOR signaling. Several clinical trials have demonstrated the efficacy of mTOR and PI3K inhibitors in overcoming endocrine resistance in hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic BC (MBC) patients...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234246/is-there-still-a-role-for-first-line-single-agent-endocrine-therapy-in-hr-and-her2-advanced-breast-cancer
#13
EDITORIAL
Luca Malorni, Laura Biganzoli
No abstract text is available yet for this article.
October 2017: Breast Care
https://www.readbyqxmd.com/read/29070992/news-from-asco-2017
#14
Marcus Schmidt, Tanja Fehm, Cornelia Liedtke, Volkmar Müller
No abstract text is available yet for this article.
September 2017: Breast Care
https://www.readbyqxmd.com/read/29070991/magnetic-resonance-imaging-after-breast-oncoplastic-surgery-an-update
#15
REVIEW
Silvia Gigli, Maria I Amabile, Francesca Di Pastena, Lucia Manganaro, Emanuele David, Massimo Monti, Valerio DʼOrazi, Carlo Catalano, Laura Ballesio
Breast-oncoplastic surgery, allowing local tumor control and a better cosmetic outcome, is oncologically safe when applied to early-stage breast cancer. Breast cancer recurrence following conservative therapy may occur during the first 5 years after treatment, with a peak incidence after 2 years. Therefore, during the follow-up period, patients undergo a series of ultrasound (US) and mammographic examinations. However, after surgery and radiation therapy, several modifications occur in the treated breast, causing difficulties in image interpretation, especially when local recurrence is suspected...
September 2017: Breast Care
https://www.readbyqxmd.com/read/29070990/a-prospective-study-to-evaluate-the-effect-of-paclitaxel-on-cardiac-ejection-fraction
#16
Mohammed Osman, Mohammad Elkady
BACKGROUND: The primary objective of the study was to evaluate the long-term changes in ejection fraction (EF) associated with paclitaxel infusion. METHODS: 50 patients were enrolled in this prospective study between 2011 and 2015. The study design included frequent follow-up visits to the clinic, EF evaluation at baseline, and regular EF assessment by echocardiography for 30 months after treatment. RESULTS: The median baseline EF was 60% (95% confidence interval (CI) 50-80%)...
September 2017: Breast Care
https://www.readbyqxmd.com/read/29070989/muscle-sparing-adm-assisted-breast-reconstruction-technique-using-complete-breast-implant-coverage-a-dual-institute-uk-based-experience
#17
Raghavan Vidya, Simon J Cawthorn
BACKGROUND: We report our early experience of a novel muscle-sparing breast (prepectoral) reconstruction technique using a pre-shaped Braxon® mesh (acellular dermal matrix) which completely wraps around the breast implant. METHODS: All patients who underwent prepectoral implant-based breast reconstruction between April 2014 and September 2015 were included in the analysis. The dermal matrix Braxon® used is a pre-shaped matrix which forms a complete implant mesh wrap...
September 2017: Breast Care
https://www.readbyqxmd.com/read/29070988/anti-phosphohistone-h3-positive-mitoses-are-linked-to-pathological-response-in-neoadjuvantly-treated-breast-cancer
#18
Martin Sillem, Sylvia Timme, Peter Bronsert, Lioudmila Bogatyreva, Dieter Hauschke, Axel Zur Hausen, Martin Werner, Elmar Stickeler
BACKGROUND: We evaluated breast cancer (BC) core biopsies taken before neoadjuvant chemotherapy (NACT) by immunohistochemistry using anti-phosphohistone H3 (PHH3) antibody to determine mitosis, and correlated the results to clinicopathological data and histopathological regression of resected tumor specimens after NACT. METHODS: 72 patients with either triple-negative (TN) or luminal type BC received NACT with epirubicin/cyclophosphamide (EC) and Taxotere®. Tumor regression was analyzed in resected specimens; pathological complete response (pCR) was achieved in 22...
September 2017: Breast Care
https://www.readbyqxmd.com/read/29070987/results-of-short-term-follow-up-in-bi-rads-3-and-4a-breast-lesions-with-a-histological-diagnosis-of-fibroadenoma-at-percutaneous-needle-biopsy
#19
Paola Clauser, Massimo Bazzocchi, Magda Marcon, Viviana Londero, Chiara Zuiani
OBJECTIVE: To evaluate the usefulness of short-term (6 months) follow-up in patients with Breast Imaging Report and Data System (BI-RADS) 3 and 4a lesions, after a diagnosis of fibroadenoma at an image-guided biopsy. PATIENTS AND METHODS: The data of 318 women with 349 biopsy-proven fibroadenomas, a 6-month follow-up, and a follow-up of ≥ 24 months were retrospectively reviewed. Information on clinical history, lesion characteristics on ultrasound (US), mammography, and magnetic resonance imaging (MRI), BI-RADS classification, and follow-up was collected...
September 2017: Breast Care
https://www.readbyqxmd.com/read/29070986/automated-semi-quantitative-analysis-of-breast-mri-potential-imaging-biomarker-for-the-prediction-of-tissue-response-to-neoadjuvant-chemotherapy
#20
Matthias Dietzel, Clemens Kaiser, Katja Pinker, Evelyn Wenkel, Matthias Hammon, Michael Uder, Barbara Bennani Baiti, Paola Clauser, Rüdiger Schulz-Wendtland, Pascal Baltzer
BACKGROUND: We aimed to investigate an automated semi-quantitative software as an imaging biomarker for the prediction of tissue response (TR) after completion of neoadjuvant chemotherapy (NAC). METHODS: Breast magnetic resonance imaging (MRI) (1.5T, protocol according to international recommendations) of 67 patients with biopsy-proven invasive breast cancer were examined before and after NAC. After completion of NAC, histopathologic assessments of TR were classified according to the Chevallier grading system (CG1/4: full/non-responder; CG2/C3: partial responder)...
September 2017: Breast Care
journal
journal
41130
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"